Search clinical trials for: SCIG

Total 26 results

Rochester General Hospital
Takeda

Recruiting

Prevalence of Humoral Dysfunction in Pts With Frequent Exacerbations of COPD, and the Effect of SCIgR for Prevention

COPD Exacerbation Acute

United States
Hvidovre University Hospital
Zealand University Hospital; Steno Diabetes Center Copenhagen

Recruiting

Pathophysiology of Diabetic Gastroparesis (PATODIAG)

Gastroparesis Due to Diabetes Mellitus Type I

Denmark
Rutgers, The State University of New Jersey

Recruiting

IVIG vs SCIG in CIDP

Chronic Inflammatory Demyelinating Polyneuropathy | CIDP | Immunoglobulin Deficiency

United States
University Health Network, Toronto

Recruiting

Subcutaneous Immunoglobulin for Myasthenia Gravis (MG_SCIG)

Myasthenia Gravis

Canada
University of Alberta
CSL Behring

Completed

A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG) (SCIG-MG)

Myasthenia Gravis

Canada
Coram Clinical Trials

Completed

Immunoglobulin, Diagnosis, Evaluation, and Key Learnings Patient Registry (IDEaL™) (IDEaL)

IVIg or SCIg Therapy in the Home or at Alternate Site

United States
University of South Florida
CSL Behring

Completed

Subcutaneous Immunoglobulin for CIDP (SCIG)

Chronic Inflammatory Demyelinating Polyneuropathy

United States
Mazen Dimachkie, MD
CSL Behring

Completed

Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis

Myasthenia Gravis

United States, Canada
Scigenia GmbH

Completed

Panaceo "MED" for IBS (Irritable Bowel Syndrome) (PCeo-17)

Irritable Bowel Syndrome | Microbial Colonization | Intestinal Disease

Austria
BriovaRx Infusion Services

Terminated

Gamma Globulin Observations and Outcomes Database for Patients With Primary Immunodeficiency Disease (GOOD-SHEPARD-PI)

Primary Immune Deficiency Disorder

United States
University Hospital, Lille
Shire

Completed

IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQvia

Primary Immunodeficiency

France
Thomas Jefferson University

Unknown

Efficacy and Mechanism of Action of SCIg in Patients With Stiff Person Syndrome (SPS)

Stiff-Person Syndrome
University Health Network, Toronto
CSL Behring

Completed

Subcutaneous Ig in Allogeneic Stem Cell Transplant Recipients (ScIGalloHCT)

Hypogammaglobulinemia

Canada
Bio Products Laboratory

Completed

Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases (SCIG03)

Common Variable Immunodeficiency | Primary Immune Deficiency Disorders | X-linked Agammaglobulinaemia | Hyperimmunoglobulin M Syndrome

United States
Bio Products Laboratory

Completed

A Multi-centre Open Study to Assess the Safety and Efficacy of Subgam®

Primary Antibody Deficiency

United Kingdom
CSL Behring

Completed

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)

Primary Immune Deficiency

Japan
CSL Behring

Completed

Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study)

Primary Immune Deficiency

Japan
CSL Behring

Completed

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)

Primary Immunodeficiency (PID)

Poland, Germany, France, Romania, Spain, Sweden, Switzerland, United Kingdom
CSL Behring

Completed

Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency

Common Variable Immunodeficiency | Agammaglobulinemia

Canada, Germany, Italy, Spain
CSL Limited

Completed

Safety Study of Subcutaneous Ig NextGen 16% in Patients With Primary Immunodeficiency

Primary Immune Deficiency

Australia, New Zealand
CSL Behring

Completed

Follow-up Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)

Primary Immune Deficiency Disorder

Japan
CSL Behring

Completed

Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy

Primary Immune Deficiency

United States
CSL Limited

Completed

Subcutaneous Ig NextGen 16% in PID Patients

Primary Immunodeficiency (PID)

Australia, New Zealand
Tel-Aviv Sourasky Medical Center
SciGen, Israel

Unknown

Efficiency of the Hepatitis B Sci-B-Vac Vaccine in HIV Positive Patients

HIV

Israel
CSL Behring

Completed

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy

Common Variable Immunodeficiency | X-linked Agammaglobulinemia | Autosomal Recessive Agammaglobulinemia

Germany, United Kingdom, France, Italy, Poland, Romania, Spain, Sweden, Switzerland
CSL Behring

Completed

Retrospective Chart Review of Subcutaneous IgG Use in Infants

Primary Immune Deficiency

United States

Search clinical trials for: SCIG

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations